Navigation Links
MAP Pharmaceuticals Reports 2008 Fourth Quarter and Year End Financial Results
Date:3/2/2009

MOUNTAIN VIEW, Calif., March 2 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2008.

The net loss for the fourth quarter ended December 31, 2008 was $21.8 million compared with $14.9 million during the same period in 2007. The net loss for the year ended December 31, 2008 was $72.9 million compared with $40.1 million for the year ended December 31, 2007.

MAP Pharmaceuticals had $44.7 million in cash, cash equivalents and short-term investments as of December 31, 2008. Subsequent to December 31, 2008, the company received a $40 million upfront payment from AstraZeneca pursuant to the worldwide Unit Dose Budesonide, UDB, collaboration signed on December 19, 2008.

"Despite the recently announced results from our UDB clinical trial, MAP Pharmaceuticals made progress in a number of areas in 2008. Moving into 2009, we have a strong balance sheet, a robust pipeline and significant upcoming milestones, including efficacy results from our first Phase 3 clinical trial of MAP0004 for the potential treatment of migraine," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals.

2008 and 2009 Year to Date Key Developments

Unit Dose Budesonide

  • Initiated our first Phase 3 clinical trial of UDB, for the potential treatment of asthma in children, and completed patient enrollment. On February 23, 2009 announced top-line results indicating that this trial did not meet its primary endpoints.
  • Entered into an exclusive worldwide collaboration with AstraZeneca to develop and commercialize UDB.
  • Announced positive results from a pharmacokinetic clinical trial of UDB, demonstrating lower syste
    '/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
2. Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals
3. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
4. Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
5. Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results
6. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
7. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
8. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
9. Endo Pharmaceuticals Appoints William Montague to Board of Directors
10. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
11. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... A new report by Milken Institute School of ... Washington University examines the challenge of maintaining enriched ... in Covered California and who are also eligible ... Program (CPSP). The CPSP, whose roots are in ... developed for low-income pregnant women, makes enriched maternity ...
(Date:10/30/2014)... Albert Einstein College of Medicine of ... will present their latest aging research at the ... Meeting. Topics include the identification of a genotype ... impairment and the cellular biology of aging. GSA ... Washington, D.C., "Einstein-Montefiore has distinguished itself in a ...
(Date:10/30/2014)... 2014—Analysis of data from an institutional patient registry ... local control, 79 percent of tumors, for medically ... SBRT from 2003 to 2012, according to research ... in Thoracic Oncology. The Symposium is sponsored by ... American Society for Radiation Oncology (ASTRO), the International ...
(Date:10/30/2014)... research group at the DFG Research Center for Regenerative ... Dresden (CRTD) demonstrated for the first time the in ... three dimensions from mouse embryonic stem cells. Correct spatial ... the dorsal/ventral axis was observed., This study has been ... Cell Reports " on 30.10.2014 ., For many years ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer ... and more, is currently hosting a sweepstakes on its ... is open to U.S. residents age 18 and over, ... One lucky winner will then be selected at random ... card to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba ...
Breaking Medicine News(10 mins):Health News:Report examines health care challenges for pregnant women enrolled in covered California 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2
... stress hormones may be disregulated in people with chronic ... that helps the body deal with physical and psychological ... stress hormone cortisol by the adrenal glands. ... tiredness. It's cause is not well understood, but some ...
... Hopkins University observed that a chest compression belt outperforms ... //When someone has a cardiac arrest, it's vital to ... soon as possible. Usually this is done by applying ... rhythm, but these are usually not available in those ...
... surgery for emphysema does not help the sickest patients, ... of the lungs - the alveoli - are progressively ... they cannot do everyday activities like climbing stairs or ... suggest that lung reduction surgery was beneficial for people ...
... high levels of C-reactive protein and low levels of albumin ... the 25% of patients who die while on kidney dialysis,// ... such patients run between five and one hundred times the ... population. ,Doctors at Johns Hopkins University have surveyed ...
... the dangers of getting a lung infection or irritation from a ... hot tub, or jacuzzi, at home or in a health club. ... clean// and well-maintained in order to avoid developing a problem with ... have investigated two patients presenting with 'hot tub lung' - a ...
... in the US have more hospital admissions for respiratory ... pollution and public health. Now doctors at the University ... on Medicare costs in a large group of the ... pollution measures in 185 metropolitan areas. They found that ...
Cached Medicine News:
(Date:10/30/2014)... NxStage® Kidney Care, Inc ., a subsidiary of NxStage® Medical, ... the grand opening ceremony of its Oak Brook, ... Street on November 20, 2014 from 3pm – 7pm. The Oak ... are committed to providing patients with enhanced access to the ... more flexible dialysis treatment options.   The facility ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Electronic ... dramatically as a result of government initiatives and ... - healthcare providers have invested over the past ... heart of health IT, and U.S. clinicians use ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)...  Nektar Therapeutics (Nasdaq: NKTR ) will ... September 30, 2014 on Thursday, November 6, 2014, after ... , president and chief executive officer, will host a ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... Webcast of the conference call can be accessed through ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
... Ontario, April 18, 2011 GlaxoSmithKline (GSK) and Valeant ... 15 April 2011 to the U.S. Food and Drug ... 2010 for the New Drug Application (NDA) for ezogabine*. ... studied for the adjunctive treatment of adults with partial-onset ...
... TARRYTOWN, N.Y., April 18, 2011 Regeneron Pharmaceuticals, Inc. ... U.S. Food and Drug Administration (FDA) has accepted for ... Trap-Eye for the treatment of the neovascular form of ... the Company,s request for priority review of its BLA. ...
Cached Medicine Technology:Regulatory Update - GSK and Valeant Respond to FDA on ezogabine 2Regulatory Update - GSK and Valeant Respond to FDA on ezogabine 3FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 2FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 3
An adhesive-backed hanger, designed for use where space is limited (fume hoods, sterile hoods, etc.). Sticks to any smooth, dry surface without damage. Resistant to chemicals and UV light....
Four Tiered Pipette Rack. Made for disposable plastic pipettes. Designed for removal of pipettes from the right side. Three tiered and left side removal racks are also available...
... Pipette Tracker is an automated solution ... calibration and performance testing for all pipettes ... directly from any balance Supports ... ISO 8655, DIN 12650, ISO 9000, NCCLS ...
... to configure for gravimetric calibration and is ... method or enter your own parameters (number ... automatically manages the calibration protocol with direct ... to the software, which establishes the calibration ...
Medicine Products: